Treatment with anti-tumor necrosis factor-α (anti-TNF-α) agents and janus kinase (JAK) inhibitors, like tofacitinib, mitigate glycolysis in the synovium of RA patients [62]. This evidence concerns the gene TNF and rheumatoid arthritis.